

## Anti-LIV-1/SLC39A6 Antibody (LadiratuzumAb)

### Introduction

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against LIV-1/ZIP6. Ladiratuzumab is conjugated with the microtubule disruptor MMAE to synthesize an antibody-active molecule conjugate (ADC) SGN-LIV1A. Ladiratuzumab can be used in breast cancer research.

### Product parameters

Alternative Names	HLIV22
Target Accession	Q13433
Target	LIV-1 / SLC39A6
CAS number	1629760-28-6
Molecular Weight	146.96 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human LIV-1 CHO Cell Line were stained with ladiratuzumab and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.0746 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

